SEC Tracker
Get the app

Scribe Therapeutics SCTX

Scribe Therapeutics Q2 FY26: revenue $1.9M; diluted EPS −$2.62

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Scribe Therapeutics reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$6.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$2.62No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$35.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Scribe Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Ocugen OCGN public float $279M, Jun 30, 2025
  2. Aspira Women's Health AWHL public float $5M, Jun 30, 2025
  3. Healthy Extracts HYEX public float $4M, Jun 30, 2025
  4. Fate Therapeutics FATE public float $113M, Jun 30, 2025
  5. Aclaris Therapeutics ACRS public float $149M, Jun 30, 2025